Gingivitis
Conditions
Keywords
Morus nigra, Mouthwash, Cytokines
Brief summary
The aim of this study is to evaluate the clinical, microbiological, and biochemical effects of Morus nigra (black mulberry) mouthwash when used as an adjunct to non-surgical periodontal treatment (scaling and root planing - SRP) in patients with generalized gingivitis. Participants will be randomly assigned to two groups: one receiving SRP only, and the other receiving SRP plus Morus nigra mouthwash twice daily for 14 days. Clinical parameters, cytokine levels in gingival crevicular fluid (TNF-alpha, IL-1beta, IL-10), and subgingival bacterial load will be assessed at baseline, 1 month, and 3 months.
Detailed description
Gingivitis is a reversible inflammatory disease of the gingiva. While mechanical plaque control (SRP) is the gold standard for treatment, herbal adjuncts like Morus nigra are of interest due to their anti-inflammatory and antioxidant properties. This randomized, controlled clinical trial will include 30 patients diagnosed with generalized gingivitis. The test group will use Morus nigra mouthwash for 14 days following SRP. Clinical indices (Gingival Index, Plaque Index) will be recorded. Biochemical analysis of cytokines (TNF-alpha, IL-1beta, IL-10) will be performed using ELISA, and microbiological analysis of subgingival plaque will be conducted using Real-time PCR.
Interventions
PROCEDUREScaling and Root Planing
Mechanical removal of dental plaque and calculus from the tooth surfaces
DIETARY_SUPPLEMENTMorus Nigra Mouthwash
Morus nigra extract based mouthwash, used 2 times a day for 14 days
Sponsors
Inonu University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of generalized gingivitis (Gingival Index \> 1). * Presence of at least 20 natural teeth. * Systemically healthy individuals. * Ability to provide informed consent.
Exclusion criteria
* Smoking or use of tobacco products. * Presence of periodontitis (no clinical attachment loss). * Use of antibiotics or anti-inflammatory drugs in the last 6 months. * Pregnancy or lactation. * History of allergy to Morus nigra or mouthwash components. * Systemic diseases (Diabetes, cardiovascular diseases, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Gingival Index (GI) | Baseline, 1 month, and 3 months. | Gingival inflammation will be assessed using the Loe and Silness Gingival Index. Higher scores indicate more severe inflammation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cytokine levels in Gingival Crevicular Fluid (GCF) | Baseline, 1 month, and 3 months | Evaluation of TNF-alpha, IL-1beta, and IL-10 levels in GCF using ELISA method. |
| Subgingival Bacterial Load | Baseline, 1 month, and 3 months | Detection and quantification of total bacterial load and specific periodontopathogenic bacteria using Real-time PCR |
Countries
Turkey (Türkiye)
Contacts
CONTACTOmer Alperen Kırmızıgul, Assistant Professor
CONTACTBurak Koçak, Dds
Outcome results
None listed